Form 4: BioLife Solutions Officer Sells Shares for Tax

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 526 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

Summary

• Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 526 shares of common stock.
• The shares were sold at a price of $26.74 per share.
• Following this transaction, Mathew beneficially owns 350,386 shares of common stock.
• The sale was executed on November 25, 2025.
• This transaction was conducted under a Rule 10b5-1(c) trading plan, adopted on February 24, 2022, specifically to satisfy tax withholding obligations associated with the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax withholding purposes under a pre-arranged 10b5-1 plan. It does not reflect a change in management's outlook on the company or its prospects, thus having a neutral sentiment.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape. Such sales are common for executives receiving equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a small, routine, and pre-planned sale for tax purposes by an executive, not indicative of a change in company fundamentals or executive confidence.
• No direct impact on employees, customers, suppliers, or creditors is implied by this filing.

Key Dates

Recommendation

The reported sale by Aby J. Mathew is a routine, non-discretionary transaction executed under a Rule 10b5-1 trading plan to cover tax withholding obligations related to restricted stock vesting. This type of insider sale is common and does not typically signal a change in the executive's confidence in the company or its future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

BioLife Solutions, BLFS, Insider Trading, Form 4, Stock Sale, Aby J. Mathew, Executive Compensation, Tax Withholding, Restricted Stock, 10b5-1 Plan